Timberlyne

Timberlyne Therapeutics is a private clinical-stage biotechnology company based in the US and is focused on the development of novel therapies for autoimmune disorders. The lead project is CM313, a potentially best-in-class monoclonal antibody targeting CD38 for autoimmune diseases. CM313 was licensed from Keymed and is an IgG1 monoclonal antibody with enhanced complement-dependent cytotoxicity. It has been clinically studied across numerous disease states, including Immune Thrombocytopenia, Systemic Lupus Erythematosus, and relapsed/refractory Multiple Myeloma.